Multivariate analysis for clinical and molecular variables of CR, OS, and EFS in younger patients
| Variables . | CR . | OS . | EFS . | |||
|---|---|---|---|---|---|---|
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| WBC count | NS | NS | NS | |||
| BM blasts | 0.011 | 0.983 (0.970-0.996) | NS | NS | ||
| FLT3 ITD or TKD | NS | NS | NS | |||
| C-KIT | NS | NS | NS | |||
| N-RAS | NS | NS | NS | |||
| NPM1 m+/DNMT3A m- | NS | .035 | 0.598 (0.370-0.964) | .060 | 0.659 (0.426-1.018) | |
| Bi-allelic CEBPA | NS | .001 | 0.365 (0.204-0.656) | .001 | 0.442 (0.271-0.722) | |
| WT1 | NS | NS | NS | |||
| ASXL1 | NS | NS | NS | |||
| DNMT3A | NS | < .001 | 2.637 (1.600-4.347) | .002 | 2.149 (1.329-3.473) | |
| MLL variants | .021 | 0.487 (0.264-0.897) | .013 | 1.671 (1.116-2.501) | .015 | 1.576 (1.093-2.273) |
| IDH1 | NS | NS | NS | |||
| IDH2 | NS | NS | NS | |||
| TET2 | .069 | 0.520 (0.257-1.053) | NS | NS | ||
| Variables . | CR . | OS . | EFS . | |||
|---|---|---|---|---|---|---|
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| WBC count | NS | NS | NS | |||
| BM blasts | 0.011 | 0.983 (0.970-0.996) | NS | NS | ||
| FLT3 ITD or TKD | NS | NS | NS | |||
| C-KIT | NS | NS | NS | |||
| N-RAS | NS | NS | NS | |||
| NPM1 m+/DNMT3A m- | NS | .035 | 0.598 (0.370-0.964) | .060 | 0.659 (0.426-1.018) | |
| Bi-allelic CEBPA | NS | .001 | 0.365 (0.204-0.656) | .001 | 0.442 (0.271-0.722) | |
| WT1 | NS | NS | NS | |||
| ASXL1 | NS | NS | NS | |||
| DNMT3A | NS | < .001 | 2.637 (1.600-4.347) | .002 | 2.149 (1.329-3.473) | |
| MLL variants | .021 | 0.487 (0.264-0.897) | .013 | 1.671 (1.116-2.501) | .015 | 1.576 (1.093-2.273) |
| IDH1 | NS | NS | NS | |||
| IDH2 | NS | NS | NS | |||
| TET2 | .069 | 0.520 (0.257-1.053) | NS | NS | ||
MLL variants include MLL fusion genes and PTD mutations.